1. Increased plasma potassium levels lower adverse outcomes in ICD patients.
2. Primary composite outcome showed 23% in intervention vs 29% in standard care.
3. Follow-up period was approximately 40 months.
4. Safety monitoring reported no treatment-related deaths.
5. The study included 1,200 patients.
6. Mean potassium levels rose from 4.0 mmol/L to 4.4 mmol/L in the intervention group.
7. Limitations included a Denmark-only population and potential biases.

Source: The New England Journal of Medicine